Given that CD44 is a biomarker of the cancer stem cell biomarker, collectively, our data indicate that we may build a bridge between mutant p53-driven chemoresistance and the CD44-enhanced stem-like phenotype in colon cancers. The gene discussed is TP53; the disease is cancer.